CLINICAL_TRIALS
trial_result
· 2021-08-23
Clinical Trial Update: A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics [Phase 2]
Summary
Phase 2 study of E6011 in rheumatoid arthritis patients inadequately responding to biologics has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eisai Co., Ltd. | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2021-08-23